01681 CONSUN PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2025) | |||
| Current | 3.22X | Oper Margin | 35.2% |
|---|---|---|---|
| LT Debt/Equity | 0.1% | Net Margin | 31.6% |
| Total Debt/Equity | 4.7% | Return on Equity | 23.8% |
| Price/Book | 2.87X | Return on Assets | 16.8% |
| (HKD 17.070) | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
| Net Profit (MHKD) | 1,200.00 | 968.27 | 864.71 | 765.68 | 721.84 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +23.9 | +12.0 | +12.9 | +6.1 | +21.9 |
| Earnings Per Share (HKD) | 1.415 | 1.179 | 1.093 | 0.968 | 0.901 |
| Earnings Per Share Growth (%) | +20.0 | +7.9 | +12.9 | +7.5 | +24.3 |
| Dividend Per Share (HKD) | 0.730 | 0.900 | 0.450 | 0.300 | 0.300 |
| P/E* (X) | 12.06 | 14.48 | 15.61 | 17.63 | 18.96 |
| Yield (%) | 4.28 | 5.27 | 2.64 | 1.76 | 1.76 |
| Dividend Share (%) | 51.59 | 76.32 | 41.16 | 30.98 | 33.31 |
| Book NAV (HKD) | 5.949 | 5.130 | 4.929 | 4.370 | 3.885 |
| Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2026-04-02 21:40:20
Latest Result
| (RMBMn) | 2025-12 | 2024-12 | Chg* (%) | 2023-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 3,417 | 2,967 | +15.2 | 2,590 |
| Operating Result | 1,200 | 1,021 | +17.5 | 864.549 |
| Associates | -1.597 | -0.066 | +2,319.7 | 0 |
| Profit Before Taxation | 1,196 | 1,020 | +17.3 | 863.703 |
| Taxation | 107.29 | 102.732 | +4.4 | 77.149 |
| Profit /( Loss) After Taxation | 1,089 | 917.374 | +18.7 | 786.554 |
| Minority Interests | 11.065 | 6.916 | +60.0 | 2.02 |
| Net Profit | 1,078 | 910.458 | +18.4 | 784.534 |
| Earnings Per Share () | 1.4151 | 1.1792 | +20.0 | 1.0933 |
| Dividend Per Share () | 0.7300 | 0.9000 | -18.9 | 0.4500 |
| Announcement Date | 2026-03-26 | 2025-03-26 | NA | 2024-03-28 |
* Annualised
Last Update Time: 2026-04-02 21:40:25
